Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01759017 · ClinicalTrials.gov registry record
PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease
A clinical trial, sponsored by Brigham and Women's Hospital.
- Terminated
- Registry status
- 8
- Enrollment target
NCT01759017 is a clinical trial that was terminated before completion, run by Brigham and Women's Hospital. The registered enrollment target is 8 participants.
The verdict
NCT01759017 was terminated before completion, sponsored by Brigham and Women's Hospital.
- TERMINATED
- Registry status
- 8 participants
- Enrollment target
Study Summary
The costs and potential complications (side effects) of therapies currently used to treat Crohn's disease could be reduced if a non-invasive test existed that determined which therapies benefit patients and which do not. A non-invasive test is a test that does not involve cutting or entering the skin. Currently, once therapies are prescribed, doctors rely solely on clinical parameters to gauge whether the therapies are helpful. This includes evaluation of overall general well-being, abdominal pain, and number of liquid stools per day. There is no established and reliable non-invasive test that can predict whether a person is responding to therapy early in the course of treatment when these evaluations may be inconclusive. During this research study we will look for changes in sugar metabolism on low-dose PET/CT before and 2 weeks after the first infusion of infliximab therapy. This is to find out if these changes can predict clinical response and steroid-free remission at two, six and 12 months, in patients with Crohn's disease.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2012-12 |
| Est. Completion | 2015-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01759017
The ClinicalTrials.gov registry entry for NCT01759017 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01759017 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01759017 about?
NCT01759017 is a clinical study titled "PET/CT to Predict Response to Infliximab Therapy in Patients With Crohn's Disease". The costs and potential complications (side effects) of therapies currently used to treat Crohn's disease could be reduced if a non-invasive test existed that determined which therapies benefit patients and which do not. A non-invasive test is a test that does not involve cutting or entering the ski...
What is the current status of trial NCT01759017?
This trial is currently terminated. The enrollment target is 8 participants. The study started on 2012-12. Estimated completion is 2015-01.
Who is sponsoring clinical trial NCT01759017?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.